SI-BONE Inc. (SIBN)
NASDAQ: SIBNHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SIBN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.07B
- EPS (TTM)
- -$0.31
- Dividend yield
- None
- 52-week range
- 11.48 – 25.92
- Day range
- 23.54 – 24.40
- Volume / Avg
- 800.98K / 709.79K
- Beta
- —
- Shares outstanding
- 45.11M
52-week range
SIBN stock today
SI-BONE (SIBN) closed at $23.73 on Nov 20, down 0.08% (-$0.02), versus the S&P 500's 3.70% decline. At this level, SIBN sits near the top of its 52-week range of $11.48 to $25.92: 8.4% below the high, set on Nov 4, 2026 and 106.7% above the low. SIBN is up 20.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 21.7%.
SI-BONE has posted a net loss over the last twelve months (EPS of -$0.31), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About SI-BONE
Company profileSI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded design with lengths capable of spanning the posterior pelvis, passing through the ipsilateral ilium, sacrum, and through the contralateral ilium.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Ms. Laura A. Francis MBA
- Headquarters
- Santa Clara, CA
- Employees
- 376
- IPO year
- 2018
- Website
- si-bone.com
Financial highlights
Full financialsIn fiscal 2025, SI-BONE generated $200.9 million in revenue, up 20.2% from fiscal 2024, its 8th consecutive year of revenue growth. SI-BONE reported a net loss of $18.9 million, compared with a loss of $30.9 million a year earlier. Gross margin was 79.6% (up from 79.0%) and operating margin -11.1%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $200.93M | $167.18M | $138.89M | $106.41M | $90.15M |
| Growth | +20.19% | +20.37% | +30.52% | +18.03% | +22.84% |
| Net income | $-18.90M | $-30.91M | $-43.34M | $-61.26M | $-56.57M |
| EPS (diluted) | $-0.44 | $-0.75 | $-1.13 | $-1.79 | $-1.71 |
Analyst forecast
ForecastConsensus (9 analysts)
strong_buy
Avg. price target
$26.78+12.85%
- Strong buy 3
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 2, 2026
- EPS actual vs est.
- $-0.11 vs $-0.13
- Surprise
- +15.38%
SIBN news
All SIBN news- SI-BONE To Present at Piper Sandler 38th Annual Healthcare Conference on December 1, 2026GlobeNewswire
- SiBone (SIBN) Hit a 52 Week High, Can the Run Continue?NasdaqSIBN, GMED
- Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%NasdaqNBIX, PTCT, RMTI, SIBN
- SI-Bone Q3 Loss Narrows As Revenue Rises 14.5%; Reaffirms FY26 Revenue OutlookNasdaqSIBN, LEN.B
- SI-BONE (SIBN) Q3 2026 Earnings Call TranscriptNasdaq
- SiBone Q3 Earnings Call HighlightsNasdaq
- SI-BONE, Inc. Reports Financial Results for the Third Quarter 2026 and Reaffirms 2026 Revenue GuidanceGlobeNewswire
- SI-BONE To Present at UBS Global Healthcare Conference on November 10, 2026GlobeNewswire
SI-BONE peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| DRTSAlpha Tau Medical Ltd. | 11.76 | +3.93% | $1.09B | vs SIBN |
| IRMDiRadimed Corporation | 81.02 | -0.30% | $1.04B | vs SIBN |
| IARTIntegra LifeSciences Holdings Corporation | 13.25 | -2.21% | $1.03B | vs SIBN |
| ATECAlphatec Holdings Inc. | 6.68 | -3.19% | $1.02B | vs SIBN |
| SGPSpyGlass Pharma Inc. | 30.43 | -1.14% | $1.02B | vs SIBN |
| TNDMTandem Diabetes Care Inc. | 17.46 | +3.93% | $1.22B | vs SIBN |
| NVCRNovoCure Limited | 10.71 | +0.19% | $1.25B | vs SIBN |
| AORTArtivion Inc. | 18.16 | -2.00% | $886.02M | vs SIBN |
Indexes, lists and sector
SI-BONE stock FAQ
What is SI-BONE's stock price today?
SIBN last traded at $23.73 as of Nov 20, 4:00 PM EST, down 0.08% on the day. Prices are delayed at least 15 minutes.
Who is SI-BONE's CEO?
Ms. Laura A. Francis MBA is the chief executive officer of SI-BONE Inc., which has about 376 employees.
What is the SIBN 52-week high?
The 52-week high for SIBN is $25.92 and the 52-week low is $11.48. The stock is currently 8.4% below its high.